

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:sssptau153cxa

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * Welcome to STN International * * * * *

| | | | |
|--------------|----|--------|--|
| NEWS | 1 | | Web Page URLs for STN Seminar Schedule - N. America |
| NEWS | 2 | | "Ask CAS" for self-help around the clock |
| NEWS | 3 | May 12 | EXTEND option available in structure searching |
| NEWS | 4 | May 12 | Polymer links for the POLYLINK command completed in REGISTRY |
| NEWS | 5 | May 27 | New UPM (Update Code Maximum) field for more efficient patent SDIs in CAPlus |
| NEWS | 6 | May 27 | CAPlus super roles and document types searchable in REGISTRY |
| NEWS | 7 | Jun 22 | STN Patent Forums to be held July 19-22, 2004 |
| NEWS | 8 | Jun 28 | Additional enzyme-catalyzed reactions added to CASREACT |
| NEWS | 9 | Jun 28 | ANTE, AQUALINE, BIOENG, CIVILENG, ENVIROENG, MECHENG, and WATER from CSA now available on STN(R) |
| NEWS | 10 | Jul 12 | BEILSTEIN enhanced with new display and select options, resulting in a closer connection to BABS |
| NEWS EXPRESS | | | MARCH 31 CURRENT WINDOWS VERSION IS V7.00A, CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP), AND CURRENT DISCOVER FILE IS DATED 26 APRIL 2004 |
| NEWS HOURS | | | STN Operating Hours Plus Help Desk Availability |
| NEWS INTER | | | General Internet Information |
| NEWS LOGIN | | | Welcome Banner and News Items |
| NEWS PHONE | | | Direct Dial and Telecommunication Network Access to STN |
| NEWS WWW | | | CAS World Wide Web Site (general information) |

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

* * * * * STN Columbus * * * * *

FILE 'HOME' ENTERED AT 12:15:10 ON 22 JUL 2004

| | | |
|--|------------|---------|
| => file caplus uspatful europatful japio medline biosis embase | | |
| COST IN U.S. DOLLARS | SINCE FILE | TOTAL |
| | ENTRY | SESSION |
| FULL ESTIMATED COST | 0.63 | 0.63 |

FILE 'CAPLUS' ENTERED AT 12:17:03 ON 22 JUL 2004

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2004 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'USPATFULL' ENTERED AT 12:17:03 ON 22 JUL 2004

CA INDEXING COPYRIGHT (C) 2004 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'EUROPATFULL' ENTERED AT 12:17:03 ON 22 JUL 2004
COPYRIGHT (c) 2004 WILA Verlag Muenchen (WILA)

FILE 'JAPIO' ENTERED AT 12:17:03 ON 22 JUL 2004
COPYRIGHT (C) 2004 Japanese Patent Office (JPO)- JAPIO

FILE 'MEDLINE' ENTERED AT 12:17:03 ON 22 JUL 2004

FILE 'BIOSIS' ENTERED AT 12:17:03 ON 22 JUL 2004
COPYRIGHT (C) 2004 BIOLOGICAL ABSTRACTS INC.(R)

FILE 'EMBASE' ENTERED AT 12:17:03 ON 22 JUL 2004
COPYRIGHT (C) 2004 Elsevier Inc. All rights reserved.

=> s (RAR antagonist)
L1 289 (RAR ANTAGONIST)

=> s l1 and (BMP? or (osteogenic protein) or OPS or cytokine#)
L2 29 L1 AND (BMP? OR (OSTEOGENIC PROTEIN) OR OPS OR CYTOKINE#)

=> s l2 and (chondrogen?)
L3 8 L2 AND (CHONDROGEN?)

=> s l3 and (solution or suspension or gel or matirx or cream or gel or film or
paste or capsule or pill or tablet or encapsul? or Microcapsule# or micropart?)
4 FILES SEARCHED...
L4 3 L3 AND (SOLUTION OR SUSPENSION OR GEL OR MATIRX OR CREAM OR
GEL OR FILM OR PASTE OR CAPSULE OR PILL OR TABLET OR ENCAPSUL?
OR MICROCAPSULE# OR MICROPART?)

=> s l4 and liposom?
L5 3 L4 AND LIPOSOM?

=> d l5 1-3 ibib abs

L5 ANSWER 1 OF 3 USPATFULL on STN
ACCESSION NUMBER: 2003:181419 USPATFULL
TITLE: Compositions and methods for affecting osteogenesis
INVENTOR(S): Underhill, T. Michael, Ontario, CANADA
Sampaio, Arthur V., Ontario, CANADA
Weston, Andrea D., Ontario, CANADA

| | NUMBER | KIND | DATE |
|-----------------------|---|------|---------------|
| PATENT INFORMATION: | US 2003125252 | A1 | 20030703 |
| APPLICATION INFO.: | US 2002-221602 | A1 | 20020912 (10) |
| | WO 2001-CA317 | | 20010313 |
| DOCUMENT TYPE: | Utility | | |
| FILE SEGMENT: | APPLICATION | | |
| LEGAL REPRESENTATIVE: | MYERS BIGEL SIBLEY & SAJOVEC, PO BOX 37428, RALEIGH, NC, 27627 | | |
| NUMBER OF CLAIMS: | 72 | | |
| EXEMPLARY CLAIM: | 1 | | |
| NUMBER OF DRAWINGS: | 6 Drawing Page(s) | | |
| LINE COUNT: | 1833 | | |

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention relates to compositions for promoting and inhibiting
osteogenesis and to methods for treating bone abnormalities resulting
from injury, toxicity or disease and for ex vivo bone tissue
engineering.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 2 OF 3 USPATFULL on STN

ACCESSION NUMBER: 2003:47877 USPATFULL
TITLE: Use of ligands for treatment of diseases responsive to retinoids
INVENTOR(S): Chambon, Pierre, Blaesheim, FRANCE
Borrelli, Emiliana, Strasbourg, FRANCE
Ghyselinck, Norbert B., Strasbourg, FRANCE
Dupe, Valerie, London, UNITED KINGDOM
Mark, Manuel, Morschwiller, FRANCE
Metzger, Daniel, Strasbourg, FRANCE
PATENT ASSIGNEE(S): Institut National de la Santa et de la Recherche
Medicale, Paris, FRANCE (non-U.S. corporation)
Centre National de la Recherche Scientifique, Paris,
FRANCE (non-U.S. corporation)
Universite Louis Pasteur, Strasbourg, FRANCE (non-U.S.
corporation)
Bristol-Myers Squibb Company, Princeton, NJ, United
States (U.S. corporation)

| | NUMBER | KIND | DATE |
|---------------------|----------------|------|--------------|
| PATENT INFORMATION: | US 6521814 | B1 | 20030218 |
| APPLICATION INFO.: | US 1998-218446 | | 19981222 (9) |

| | NUMBER | DATE |
|-----------------------|---|---------------|
| PRIORITY INFORMATION: | US 1997-68471P | 19971222 (60) |
| DOCUMENT TYPE: | Utility | |
| FILE SEGMENT: | GRANTED | |
| PRIMARY EXAMINER: | Reynolds, Deborah J. | |
| ASSISTANT EXAMINER: | Sorbello, Eleanor | |
| LEGAL REPRESENTATIVE: | Sterne, Kessler Goldstein & Fox | |
| NUMBER OF CLAIMS: | 73 | |
| EXEMPLARY CLAIM: | 1 | |
| NUMBER OF DRAWINGS: | 124 Drawing Figure(s); 51 Drawing Page(s) | |
| LINE COUNT: | 5178 | |

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention relates to methods for treatment of neurological disease by administering an agent which interacts with a retinoid receptor associated with the neurological disease. The invention is also related to a method of modulating dopamine receptor synthesis by introducing an agent that interacts with a retinoid receptor associated with the dopamine receptor synthesis. The invention is further related to a transgenic animal, e.g., mouse, and mammalian cell line, which is deficient in the normal synthesis of one or more receptors of RAR α , β , γ and RXR, and cell line thereof.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 3 OF 3 EUROPATFULL COPYRIGHT 2004 WILA on STN

GRANTED PATENT - ERTEILTES PATENT - BREVET DELIVRE

ACCESSION NUMBER: 1131067 EUROPATFULL EW 200420 FS PS
TITLE: COMPOSITION AND USE OF RAR ANTAGONISTS FOR PROMOTING
CHONDROGENESIS.
ZUBEREITUNG UND VERWENDUNG VON RAR ANTAGONISTEN ZUR
FORDERUNG DER **CHONDROGENESE**.
COMPOSITION A BASE D'ANTAGONISTES DES RAR ET SON
UTILISATION POUR FAVORISER LA **CHONDROGENESE**.
INVENTOR(S): UNDERHILL, Tully Michael, Univ. Western of Ontario, Div.
of Oral Biology, School of Dentistry, London, Ontario
N6A 5C1, CA;
WESTON, Andrea, Dawn, Univ.of Western Ontario, The

PATENT ASSIGNEE(S): Faculty of Med. & Dentistry, Dep.of Phys., London,
 Ontario N6A 5C1, CA
 The University of Western Ontario, Office of Industry
 Liason, Stevenson-Lawson Building, Room 319, London,
 Ontario N6A 5B8, CA
 PATENT ASSIGNEE NO: 1820961
 AGENT: Holliday, Louise Caroline, D Young & Co, 21 New Fetter
 Lane, London EC4A 1DA, GB
 AGENT NUMBER: 95451
 OTHER SOURCE: MEPB2004021 EP 1131067 B1 0035
 SOURCE: Wila-EPS-2004-H20-T1
 DOCUMENT TYPE: Patent
 LANGUAGE: Anmeldung in Englisch; Veroeffentlichung in Englisch
 DESIGNATED STATES: R AT; R BE; R CH; R CY; R DE; R DK; R ES; R FI; R FR; R
 GB; R GR; R IE; R IT; R LI; R LU; R MC; R NL; R PT; R
 SE; R AL; R LT; R LV; R MK; R RO; R SI
 PATENT INFO.PUB.TYPE: EPB1 EUROPAEISCHE PATENTSCHRIFT (Internationale
 Anmeldung)

PATENT INFORMATION:

| | PATENT NO | KIND | DATE |
|------------------------|--|--------|---------------|
| | EP 1131067 | B1 | 20040512 |
| 'OFFENLEGUNGS' DATE: | | | 20010912 |
| APPLICATION INFO.: | EP 1999-955613 | | 19991119 |
| PRIORITY APPLN. INFO.: | CA 1998-2254429 | | 19981119 |
| RELATED DOC. INFO.: | WO 99-CA1106 | 991119 | INTAKZ |
| | WO 2000030635 | 000602 | INTPNR |
| REFERENCE PAT. INFO.: | WO 98-08546 A | | WO 99-24415 A |
| | US 5827500 A | | |
| REF. NON-PATENT-LIT.: | KOYAMA E ET AL: "Retinoid signaling is required for chondrocyte maturation and endochondral bone formation during limb skeletogenesis." DEVELOPMENTAL BIOLOGY, (1999 APR 15) 208 (2) 375-91., XP000879298 PATENT ABSTRACTS OF JAPAN vol. 1998, no. 10, 31 August 1998 (1998-08-31) & JP10114757 A (SHUDO KOICHI), 6 May 1998 (1998-05-06) STANDEVEN A M ET AL: "Retinoid-induced epiphyseal plate closure in guinea pigs." FUNDAMENTAL AND APPLIED TOXICOLOGY, (1996 NOV) 34 (1) 91-8., XP000879170 KOYAMA, E. ET AL: "Retinoids and their nuclear receptors promote the completion of chondrocyte maturation during limb skeletogenesis." MOLECULAR BIOLOGY OF THE CELL, (NOV., 1997) VOL. 8, NO. SUPPL., PP. 71A. MEETING INFO.: 37TH ANNUAL MEETING OF THE AMERICAN SOCIETY FOR CELL BIOLOGY WASHINGTON, D.C., USA DECEMBER 13-17, 1997 AMERICAN SOCIETY FOR CELL BIOLOGY., XP000879148 NUKA S (REPRINT) ET AL: "All-trans retinoic acid inhibits dexamethasone-induced ALP activity and mineralization in human osteoblastic cell line SV HFO" CELL STRUCTURE AND FUNCTION, (FEB 1997) VOL. 22, NO. 1, PP. 27-32. PUBLISHER: JAPAN SOC CELL BIOLOGY, SHIMOTACHIURI OGAWA-HIGASHI, KAMIKYOKU KYOTO 602, JAPAN. ISSN: 0386-7196., XP000879088 SAPPORO MED UNIV, SCH MED, DEPT PATHOL, CHUO KU, S1, W17, SAPPORO, HOKKAIDO 060, JAPAN (Reprint);SAPPORO MED UNIV, SCH MED, DEPT ORTHOPAED SURG, CHUO KU, SAPPORO, HOKKAIDO 060, JAPAN VON SCHROEDER H P ET AL: "The effects of natural and synthetic retinoids on the differentiation of RCJ C5.18 chondrogenic cells." TERATOLOGY, (1994 JUL) 50 (1) 54-62., XP000653320 JIANG: "Modulation of limb bud chondrogenesis by retinoic acid and retinoic acid receptors." DEVELOPMENTAL BIOLOGY, vol. 39, no. 4, 1995, XP000884176 | | |

=> d 13 1-8 ibib abs

L3 ANSWER 1 OF 8 CAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 2000:368088 CAPLUS
DOCUMENT NUMBER: 133:828
TITLE: Composition and use of RAR antagonists for promoting
chondrogenesis
INVENTOR(S): Underhill, Tully Michael; Weston, Andrea Dawn
PATENT ASSIGNEE(S): The University of Western Ontario, Can.
SOURCE: PCT Int. Appl., 63 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|------|----------|-----------------|----------|
| WO 2000030635 | A1 | 20000602 | WO 1999-CA1106 | 19991119 |
| W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM | | | | |
| RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG | | | | |
| EP 1131067 | A1 | 20010912 | EP 1999-955613 | 19991119 |
| EP 1131067 | B1 | 20040512 | | |
| R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO | | | | |
| JP 2002530331 | T2 | 20020917 | JP 2000-583518 | 19991119 |
| AU 764394 | B2 | 20030814 | AU 2000-12552 | 19991119 |
| AU 2000012552 | A5 | 20000613 | | |
| US 2002061514 | A1 | 20020523 | US 2001-957456 | 20010921 |
| PRIORITY APPLN. INFO.: | | | | |
| CA 1998-2254429 A 19981119 | | | | |
| WO 1999-CA1106 W 19991119 | | | | |
| US 2000-234242P P 20000921 | | | | |

AB The invention provides compns. comprising a **RAR antagonist** for promoting **chondrogenesis**, as well as methods employing such compns. for treating cartilage and associated bone abnormalities resulting from injury or disease and for ex vivo tissue engineering.

REFERENCE COUNT: 11 THERE ARE 11 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 2 OF 8 CAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 2000:147914 CAPLUS
DOCUMENT NUMBER: 132:261066
TITLE: Regulation of skeletal progenitor differentiation by the **BMP** and retinoid signaling pathways
AUTHOR(S): Weston, Andrea D.; Rosen, Vicki; Chandraratna, Roshantha A. S.; Underhill, T. Michael
CORPORATE SOURCE: Department of Physiology, Faculty of Medicine & Dentistry, The University of Western Ontario, London, ON, N6A 5C1, Can.
SOURCE: Journal of Cell Biology (2000), 148(4), 679-690
CODEN: JCLBA3; ISSN: 0021-9525
PUBLISHER: Rockefeller University Press
DOCUMENT TYPE: Journal
LANGUAGE: English
AB The generation of the paraxial skeleton requires that commitment and

differentiation of skeletal progenitors is precisely coordinated during limb out-growth. Several signaling mols. have been identified that are important in specifying the pattern of these skeletal primordia. Very little is known, however, about the mechanisms regulating the differentiation of limb mesenchyme into chondrocytes. Overexpression of RAR α in transgenic animals interferes with **chondrogenesis** and leads to appendicular skeletal defects. Further anal. of these animals shows that expression of the transgene in chondroprogenitors maintains a prechondrogenic phenotype and prevents chondroblast differentiation even in the presence of **BMPs**, which are known stimulators of cartilage formation. Moreover, an **RAR antagonist** accelerates chondroblast differentiation as demonstrated by the emergence of collagen type II-expressing cells much earlier than in control or **BMP**-treated cultures. Addition of Noggin to limb mesenchyme cultures inhibits cartilage formation and the appearance of precartilaginous condensations. In contrast, abrogation of retinoid signaling is sufficient to induce the expression of the chondroblastic phenotype in the presence of Noggin. These findings show that **BMP** and RAR-signaling pathways appear to operate independently to coordinate skeletal development, and that retinoid signaling can function in a **BMP**-independent manner to induce cartilage formation. Thus, retinoid signaling appears to play a novel and unexpected role in skeletogenesis by regulating the emergence of chondroblasts from skeletal progenitors.

REFERENCE COUNT: 63 THERE ARE 63 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 3 OF 8 USPATFULL on STN

ACCESSION NUMBER: 2003:181419 USPATFULL

TITLE: Compositions and methods for affecting osteogenesis

INVENTOR(S): Underhill, T. Michael, Ontario, CANADA

Sampaio, Arthur V., Ontario, CANADA

Weston, Andrea D., Ontario, CANADA

| | NUMBER | KIND | DATE |
|-----------------------|--|------|---------------|
| PATENT INFORMATION: | US 2003125252 | A1 | 20030703 |
| APPLICATION INFO.: | US 2002-221602 | A1 | 20020912 (10) |
| | WO 2001-CA317 | | 20010313 |
| DOCUMENT TYPE: | Utility | | |
| FILE SEGMENT: | APPLICATION | | |
| LEGAL REPRESENTATIVE: | MYERS BIGEL SIBLEY & SAJOVEC, PO BOX 37428, RALEIGH, NC, 27627 | | |
| NUMBER OF CLAIMS: | 72 | | |
| EXEMPLARY CLAIM: | 1 | | |
| NUMBER OF DRAWINGS: | 6 Drawing Page(s) | | |
| LINE COUNT: | 1833 | | |

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention relates to compositions for promoting and inhibiting osteogenesis and to methods for treating bone abnormalities resulting from injury, toxicity or disease and for ex vivo bone tissue engineering.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 4 OF 8 USPATFULL on STN

ACCESSION NUMBER: 2003:47877 USPATFULL

TITLE: Use of ligands for treatment of diseases responsive to retinoids

INVENTOR(S): Chambon, Pierre, Blaesheim, FRANCE

Borrelli, Emiliana, Strasbourg, FRANCE

Ghyselinck, Norbert B., Strasbourg, FRANCE

Dupe, Valerie, London, UNITED KINGDOM

Mark, Manuel, Morchwiller, FRANCE

PATENT ASSIGNEE(S): Metzger, Daniel, Strasbourg, FRANCE
Institut National de la Santa et de la Recherche
Medicale, Paris, FRANCE (non-U.S. corporation)
Centre National de la Recherche Scientifique, Paris,
FRANCE (non-U.S. corporation)
Universite Louis Pasteur, Strasbourg, FRANCE (non-U.S.
corporation)
Bristol-Myers Squibb Company, Princeton, NJ, United
States (U.S. corporation)

| | NUMBER | KIND | DATE |
|---------------------|----------------|------|--------------|
| PATENT INFORMATION: | US 6521814 | B1 | 20030218 |
| APPLICATION INFO.: | US 1998-218446 | | 19981222 (9) |

| | NUMBER | DATE |
|-----------------------|---|---------------|
| PRIORITY INFORMATION: | US 1997-68471P | 19971222 (60) |
| DOCUMENT TYPE: | Utility | |
| FILE SEGMENT: | GRANTED | |
| PRIMARY EXAMINER: | Reynolds, Deborah J. | |
| ASSISTANT EXAMINER: | Sorbello, Eleanor | |
| LEGAL REPRESENTATIVE: | Sterne, Kessler Goldstein & Fox | |
| NUMBER OF CLAIMS: | 73 | |
| EXEMPLARY CLAIM: | 1 | |
| NUMBER OF DRAWINGS: | 124 Drawing Figure(s); 51 Drawing Page(s) | |
| LINE COUNT: | 5178 | |

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention relates to methods for treatment of neurological disease by administering an agent which interacts with a retinoid receptor associated with the neurological disease. The invention is also related to a method of modulating dopamine receptor synthesis by introducing an agent that interacts with a retinoid receptor associated with the dopamine receptor synthesis. The invention is further related to a transgenic animal, e.g., mouse, and mammalian cell line, which is deficient in the normal synthesis of one or more receptors of RAR α , β , γ and RXR, and cell line thereof.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 5 OF 8 EUROPATFULL COPYRIGHT 2004 WILA on STN

GRANTED PATENT - ERTEILTES PATENT - BREVET DELIVRE

ACCESSION NUMBER: 1131067 EUROPATFULL EW 200420 FS PS
TITLE: COMPOSITION AND USE OF RAR ANTAGONISTS FOR PROMOTING
CHONDROGENESIS.
ZUBEREITUNG UND VERWENDUNG VON RAR ANTAGONISTEN ZUR
FORDERUNG DER **CHONDROGENESE**.
COMPOSITION A BASE D'ANTAGONISTES DES RAR ET SON
UTILISATION POUR FAVORISER LA **CHONDROGENESE**.
INVENTOR(S): UNDERHILL, Tully Michael, Univ. Western of Ontario, Div.
of Oral Biology, School of Dentistry, London, Ontario
N6A 5C1, CA;
WESTON, Andrea, Dawn, Univ. of Western Ontario, The
Faculty of Med. & Dentistry, Dep. of Phys., London,
Ontario N6A 5C1, CA
PATENT ASSIGNEE(S): The University of Western Ontario, Office of Industry
Liason, Stevenson-Lawson Building, Room 319, London,
Ontario N6A 5B8, CA
PATENT ASSIGNEE NO: 1820961
AGENT: Holliday, Louise Caroline, D Young & Co, 21 New Fetter
Lane, London EC4A 1DA, GB
AGENT NUMBER: 95451

OTHER SOURCE: MEPB2004021 EP 1131067 B1 0035
 SOURCE: Wila-EPS-2004-H20-T1
 DOCUMENT TYPE: Patent
 LANGUAGE: Anmeldung in Englisch; Veroeffentlichung in Englisch
 DESIGNATED STATES: R AT; R BE; R CH; R CY; R DE; R DK; R ES; R FI; R FR; R GB; R GR; R IE; R IT; R LI; R LU; R MC; R NL; R PT; R SE; R AL; R LT; R LV; R MK; R RO; R SI
 PATENT INFO.PUB.TYPE: EPB1 EUROPÄISCHE PATENTSCHRIFT (Internationale Anmeldung)

PATENT INFORMATION:

| | PATENT NO | KIND DATE |
|------------------------|---|---------------|
| | EP 1131067 | B1 20040512 |
| 'OFFENLEGUNGS' DATE: | | 20010912 |
| APPLICATION INFO.: | EP 1999-955613 | 19991119 |
| PRIORITY APPLN. INFO.: | CA 1998-2254429 | 19981119 |
| RELATED DOC. INFO.: | WO 99-CA1106 | 991119 INTAKZ |
| | WO 2000030635 | 000602 INTPNR |
| REFERENCE PAT. INFO.: | WO 98-08546 A | WO 99-24415 A |
| | US 5827500 A | |
| REF. NON-PATENT-LIT.: | KOYAMA E ET AL: "Retinoid signaling is required for chondrocyte maturation and endochondral bone formation during limb skeletogenesis." DEVELOPMENTAL BIOLOGY, (1999 APR 15) 208 (2) 375-91., XP000879298 PATENT ABSTRACTS OF JAPAN vol. 1998, no. 10, 31 August 1998 (1998-08-31) & JP10114757 A (SHUDO KOICHI), 6 May 1998 (1998-05-06) STANDEVEN A M ET AL: "Retinoid-induced epiphyseal plate closure in guinea pigs." FUNDAMENTAL AND APPLIED TOXICOLOGY, (1996 NOV) 34 (1) 91-8., XP000879170 KOYAMA, E. ET AL: "Retinoids and their nuclear receptors promote the completion of chondrocyte maturation during limb skeletogenesis." MOLECULAR BIOLOGY OF THE CELL, (NOV., 1997) VOL. 8, NO. SUPPL., PP. 71A. MEETING INFO.: 37TH ANNUAL MEETING OF THE AMERICAN SOCIETY FOR CELL BIOLOGY WASHINGTON, D.C., USA DECEMBER 13-17, 1997 AMERICAN SOCIETY FOR CELL BIOLOGY., XP000879148 NUKA S (REPRINT) ET AL: "All-trans retinoic acid inhibits dexamethasone-induced ALP activity and mineralization in human osteoblastic cell line SV HFO" CELL STRUCTURE AND FUNCTION, (FEB 1997) VOL. 22, NO. 1, PP. 27-32. PUBLISHER: JAPAN SOC CELL BIOLOGY, SHIMOTACHIURI OGAWA-HIGASHI, KAMIKYOKU KYOTO 602, JAPAN. ISSN: 0386-7196., XP000879088 SAPPORO MED UNIV, SCH MED, DEPT PATHOL, CHUO KU, S1, W17, SAPPORO, HOKKAIDO 060, JAPAN (Reprint); SAPPORO MED UNIV, SCH MED, DEPT ORTHOPAED SURG, CHUO KU, SAPPORO, HOKKAIDO 060, JAPAN VON SCHROEDER H P ET AL: "The effects of natural and synthetic retinoids on the differentiation of RCJ C5.18 chondrogenic cells." TERATOLOGY, (1994 JUL) 50 (1) 54-62., XP000653320 JIANG: "Modulation of limb bud chondrogenesis by retinoic acid and retinoic acid receptors." DEVELOPMENTAL BIOLOGY, vol. 39, no. 4, 1995, XP000884176 | |

L3 ANSWER 6 OF 8

ACCESSION NUMBER: 2000153508 MEDLINE

DOCUMENT NUMBER: PubMed ID: 10684250

TITLE: Regulation of skeletal progenitor differentiation by the BMP and retinoid signaling pathways.

AUTHOR: Weston A D; Rosen V; Chandraratna R A; Underhill T M

CORPORATE SOURCE: Division of Oral Biology, School of Dentistry, The University of Western Ontario, London, Ontario, Canada.

SOURCE: Journal of cell biology, (2000 Feb 21) 148 (4) 679-90.
 Journal code: 0375356. ISSN: 0021-9525.

PUB. COUNTRY: United States
DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)
LANGUAGE: English
FILE SEGMENT: Priority Journals
ENTRY MONTH: 200003
ENTRY DATE: Entered STN: 20000327
Last Updated on STN: 20000327
Entered Medline: 20000313

AB The generation of the paraxial skeleton requires that commitment and differentiation of skeletal progenitors is precisely coordinated during limb outgrowth. Several signaling molecules have been identified that are important in specifying the pattern of these skeletal primordia. Very little is known, however, about the mechanisms regulating the differentiation of limb mesenchyme into chondrocytes. Overexpression of RARalpha in transgenic animals interferes with **chondrogenesis** and leads to appendicular skeletal defects (Cash, D.E., C.B. Bock, K. Schughart, E. Linney, and T.M. Underhill. 1997. J. Cell Biol. 136:445-457). Further analysis of these animals shows that expression of the transgene in chondroprogenitors maintains a prechondrogenic phenotype and prevents chondroblast differentiation even in the presence of **BMPs**, which are known stimulators of cartilage formation. Moreover, an **RAR antagonist** accelerates chondroblast differentiation as demonstrated by the emergence of collagen type II-expressing cells much earlier than in control or **BMP**-treated cultures. Addition of Noggin to limb mesenchyme cultures inhibits cartilage formation and the appearance of precartilaginous condensations. In contrast, abrogation of retinoid signaling is sufficient to induce the expression of the chondroblastic phenotype in the presence of Noggin. These findings show that **BMP** and RAR-signaling pathways appear to operate independently to coordinate skeletal development, and that retinoid signaling can function in a **BMP**-independent manner to induce cartilage formation. Thus, retinoid signaling appears to play a novel and unexpected role in skeletogenesis by regulating the emergence of chondroblasts from skeletal progenitors.

L3 ANSWER 7 OF 8 BIOSIS COPYRIGHT 2004 BIOLOGICAL ABSTRACTS INC. on STN
ACCESSION NUMBER: 2000:142678 BIOSIS
DOCUMENT NUMBER: PREV200000142678
TITLE: Regulation of skeletal progenitor differentiation by the **BMP** and retinoid signaling pathways.
AUTHOR(S): Weston, Andrea D.; Rosen, Vicki; Chandraratna, Roshantha A. S.; Underhill, T. Michael [Reprint author]
CORPORATE SOURCE: School of Dentistry, Faculty of Medicine and Dentistry, University of Western Ontario, London, ON, N6A 5C1, Canada
SOURCE: Journal of Cell Biology, (Feb. 21, 2000) Vol. 148, No. 4, pp. 679-690. print.
CODEN: JCLBA3. ISSN: 0021-9525.
DOCUMENT TYPE: Article
LANGUAGE: English
ENTRY DATE: Entered STN: 19 Apr 2000
Last Updated on STN: 4 Jan 2002

AB The generation of the paraxial skeleton requires that commitment and differentiation of skeletal progenitors is precisely coordinated during limb outgrowth. Several signaling molecules have been identified that are important in specifying the pattern of these skeletal primordia. Very little is known, however, about the mechanisms regulating the differentiation of limb mesenchyme into chondrocytes. Overexpression of RARalpha in transgenic animals interferes with **chondrogenesis** and leads to appendicular skeletal defects (Cash, D.E., C.B. Bock, K. Schughart, E. Linney, and T.M. Underhill. 1997. J. Cell Biol. 136:445-457). Further analysis of these animals shows that expression of the transgene in chondroprogenitors maintains a prechondrogenic phenotype and prevents chondroblast differentiation even in the presence of **BMPs**, which are known stimulators of cartilage formation.

Moreover, an **RAR antagonist** accelerates chondroblast differentiation as demonstrated by the emergence of collagen type II-expressing cells much earlier than in control or **BMP**-treated cultures. Addition of Noggin to limb mesenchyme cultures inhibits cartilage formation and the appearance of precartilaginous condensations. In contrast, abrogation of retinoid signaling is sufficient to induce the expression of the chondroblastic phenotype in the presence of Noggin. These findings show that **BMP** and RAR-signaling pathways appear to operate independently to coordinate skeletal development, and that retinoid signaling can function in a **BMP**-independent manner to induce cartilage formation. Thus, retinoid signaling appears to play a novel and unexpected role in skeletogenesis by regulating the emergence of chondroblasts from skeletal progenitors.

L3 ANSWER 8 OF 8 EMBASE COPYRIGHT 2004 ELSEVIER INC. ALL RIGHTS RESERVED.
on STN

ACCESSION NUMBER: 2000316638 EMBASE
TITLE: Regulation of skeletal progenitor differentiation by the **BMP** and retinoid signaling pathways.
AUTHOR: Weston A.D.; Rosen V.; Chandraratna R.A.S.; Underhill T.M.
CORPORATE SOURCE: T.M. Underhill, School of Dentistry, Faculty of Medicine/Dentistry, University of Western Ontario, London, Ont. N6A 5C1, Canada. tunderhi@julian.uwo.ca
SOURCE: Journal of Cell Biology, (21 Feb 2000) 148/4 (679-690).
Refs: 63
ISSN: 0021-9525 CODEN: JCLBA3
COUNTRY: United States
DOCUMENT TYPE: Journal; Article
FILE SEGMENT: 021 Developmental Biology and Teratology
LANGUAGE: English
SUMMARY LANGUAGE: English

AB The generation of the paraxial skeleton requires that commitment and differentiation of skeletal progenitors is precisely coordinated during limb outgrowth. Several signaling molecules have been identified that are important in specifying the pattern of these skeletal primordia. Very little is known, however, about the mechanisms regulating the differentiation of limb mesenchyme into chondrocytes. Overexpression of **RAR α** in transgenic animals interferes with **chondrogenesis** and leads to appendicular skeletal defects (Cash, D.E., C.B. Bock, K. Schughart, E. Linney, and T.M. Underhill. 1997. J. Cell Biol. 136:445-457). Further analysis of these animals shows that expression of the transgene in chondroprogenitors maintains a prechondrogenic phenotype and prevents chondroblast differentiation even in the presence of **BMPs**, which are known stimulators of cartilage formation. Moreover, an **RAR antagonist** accelerates chondroblast differentiation as demonstrated by the emergence of collagen type II-expressing cells much earlier than in control or **BMP**-treated cultures. Addition of Noggin to limb mesenchyme cultures inhibits cartilage formation and the appearance of precartilaginous condensations. In contrast, abrogation of retinoid signaling is sufficient to induce the expression of the chondroblastic phenotype in the presence of Noggin. These findings show that **BMP** and RAR-signaling pathways appear to operate independently to coordinate skeletal development, and that retinoid signaling can function in a **BMP**-independent manner to induce cartilage formation. Thus, retinoid signaling appears to play a novel and unexpected role in skeletogenesis by regulating the emergence of chondroblasts from skeletal progenitors.

=>